Emerging vaccine therapy approaches for prostate cancer.
暂无分享,去创建一个
[1] P. Kantoff,et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Higano,et al. Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer , 2008, Cancer.
[3] I. Lowy,et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) , 2008 .
[4] S. Steinberg,et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design , 2008 .
[5] D. Gabrilovich,et al. Tumor escape mechanism governed by myeloid-derived suppressor cells. , 2008, Cancer research.
[6] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Levitt,et al. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. , 2007, Cancer research.
[9] J. Nemunaitis,et al. Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.
[10] E. Small,et al. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.
[11] K. Slawin,et al. An essential role for Akt1 in dendritic cell function and tumor immunotherapy , 2006, Nature Biotechnology.
[12] P. Pisa,et al. Tumor escape mechanisms in prostate cancer , 2006, Cancer Immunology, Immunotherapy.
[13] J. Sosman,et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide , 2006, Cancer Immunology, Immunotherapy.
[14] P. Schellhammer,et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Small,et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy , 2006, Cancer.
[16] S. Piantadosi,et al. Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer , 2006, Clinical Cancer Research.
[17] L. Chess,et al. Regulation of immune responses by T cells. , 2006, The New England journal of medicine.
[18] E. Small,et al. Prostate cancer immunology: biology, therapeutics, and challenges. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Donna Niedzwiecki,et al. Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.
[20] Rana A K Singh,et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo , 2005, Nature Medicine.
[21] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[22] C. Figdor,et al. Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.
[23] T. Clackson,et al. Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers , 2001, Journal of clinical pharmacology.
[24] M. Peshwa,et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Steinberg,et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines , 2000, Cancer Immunology, Immunotherapy.
[26] E. Small,et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] T. Schumacher,et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.
[28] M. Davis,et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. , 1999, Cancer research.
[29] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[30] V. Apostolopoulos,et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. , 1997, The Journal of clinical investigation.
[31] D. Baxby. Recombinant poxvirus vaccines , 1993 .
[32] P. Cresswell,et al. NK susceptibility varies inversely with target cell class I HLA antigen expression. , 1987, Journal of immunology.
[33] H. Ragde,et al. Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease , 1999, The Prostate.